Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|August 18, 1999
Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin KK J Duffy, L H Ridgers, R L DesJarlais, et al.
Gene|February 1, 1992
The yeast cyclophilin multigene family: purification, cloning and characterization of a new isoformM M McLaughlin, M J Bossard, P L Koser, et al.
Chemistry & Biology|July 1, 1995
Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interfaceJ I Luengo, D S Yamashita, D Dunnington, et al.
Gene|July 30, 1993
The tyrosine89 residue of yeast FKBP12 is required for rapamycin bindingP L Koser, W K Eng, M J Bossard, et al.
The Journal of Biological Chemistry|May 24, 1996
Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identificationM J Bossard, T A Tomaszek, S K Thompson, et al.
Biochemistry|January 8, 2000
Mechanism of inhibition of cathepsin K by potent, selective 1, 5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteasesM J Bossard, T A Tomaszek, M A Levy, et al.
Gene|December 1, 1991
The CYP2 gene of Saccharomyces cerevisiae encodes a cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase with an N-terminal signal sequenceP L Koser, D J Bergsma, R Cafferkey, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 1, 1997
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivoB J Votta, M A Levy, A Badger, et al.
Hamostaseologie|September 11, 2012
BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisationP L Turecek, M J Bossard, M Graninger, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Pageof 2